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Background
With an estimated 300 million individuals affected world-
wide, asthma is associated with substantial social and eco-
nomic burden. The cost of treating uncontrolled severe
allergic asthma (SAA) is high encompassing a variety of
direct medical costs and indirect costs. We present data
on real-world healthcare utilization (direct) and school/
work absence (indirect) in uncontrolled SAA patients
receiving omalizumab in the eXpeRience registry.
Methods
eXpeRience was a 2-year, global, single-arm, observa-
tional registry. Data were collected on real-world
effectiveness, safety and use of omalizumab in patients
with uncontrolled SAA. Asthma-related healthcare
utilization (hospitalizations, emergency room visits or
unscheduled doctor visits) and number of days missed
from school/work were recorded.
Results
The intent-to-treat population comprised 916 (97.1%)
patients. Compared with the pre-treatment period, there
were reductions in healthcare utilization and school/
work absence after 12 and 24 months of omalizumab
treatment.
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Table 1
Variable, mean (SD); n Pre-treatment° (N=916) 12 months (N=734) 24 months (N=643)
Asthma-related hospitalizations 0.7 (1.32); 882 0.1 (0.43); 702 0.1 (0.41); 628
Duration of hospitalization stay due to asthma, days 5.3 (11.05); 852 0.7 (3.84); 703 0.5 (3.39); 628
Asthma-related emergency room visits 1.8 (2.87); 867 0.2 (0.64); 700 0.1 (0.32); 627
Unscheduled asthma-related doctor visits 3.8 (4.79); 823 0.7 (1.43); 684 0.4 (0.99); 619
Asthma-related medical healthcare uses* 6.2 (6.97); 811 1.0 (1.96); 684 0.5 (1.28); 618
Absence from work due to asthma#, days 26.4 (49.61); 347 3.5 (17.28); 295 1.0 (4.66); 296
Absence from school due to asthma#, days 20.7 (27.49); 57 1.6 (4.28); 59 1.9 (5.46); 58
Table 1 shows annualized data (12 month combined 16 weeks, 8 and 12 month data; 24 month combined 18 and 24 month data).
n – number of patients with data recorded. °Within 12 months prior to start of omalizumab treatment. *Total number of asthma-related healthcare uses was
calculated if data for asthma-related hospitalizations, emergency room visits and unscheduled doctor visits were available. #Excluded those patients for whom
this category was not applicable. Conclusion: Results from the eXpeRience registry showed that omalizumab reduced healthcare utilization and the number of
days missed from school or work by asthma patients in a real-world setting. Thus, omalizumab treatment was associated with a positive and substantial impact
on the direct and indirect costs linked with uncontrolled SAA.
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